K
Kevin J. Duffy
Researcher at GlaxoSmithKline
Publications - 57
Citations - 3597
Kevin J. Duffy is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: RNA polymerase & Receptor. The author has an hindex of 27, co-authored 56 publications receiving 3080 citations. Previous affiliations of Kevin J. Duffy include Harvard University & Indiana University.
Papers
More filters
Journal ArticleDOI
Targeting lactate dehydrogenase-A inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor initiating cells
Han Xie,Jun-ichi Hanai,Jian-Guo Ren,Lev Kats,Kerri Burgess,Parul Bhargava,Sabina Signoretti,Julia Billiard,Kevin J. Duffy,Aaron K. Grant,Xiaoen Wang,Pawel Lorkiewicz,Sabrina Schatzman,Michael Bousamra,Andrew N. Lane,Richard M. Higashi,Teresa W.-M. Fan,Pier Paolo Pandolfi,Vikas P. Sukhatme,Pankaj Seth +19 more
TL;DR: It is demonstrated that inactivation of LDH-A in mouse models of NSCLC driven by oncogenic K-RAS or EGFR leads to decreased tumorigenesis and disease regression in established tumors, and LDH -A can be a viable therapeutic target forNSCLC, including cancer stem cell-dependent drug-resistant tumors.
Journal ArticleDOI
Design of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu Joshi M,George Scott Pesiridis,Jingsong Yang,Nestor O. Concha,Robert Singhaus,Shu-Yun Zhang,Jean-Luc Tran,P. Moore,Stephanie Lehmann,H.C. Eberl,Marcel Muelbaier,Jessica L. Schneck,Jim Clemens,Michael Adam,John F. Mehlmann,Joseph J. Romano,A. Morales,Jianxing Kang,Lara Kathryn Leister,Todd L. Graybill,Adam Kenneth Charnley,Guosen Ye,Neysa Nevins,K. Behnia,Amaya I. Wolf,Viera Kasparcova,Kelvin Nurse,Liping Wang,Yufeng Li,Michael Klein,Christopher B. Hopson,Jeffrey Guss,Marcus Bantscheff,Giovanna Bergamini,Reilly,Yiqian Lian,Kevin J. Duffy,Jerry L. Adams,Kevin Foley,Peter J. Gough,Robert W. Marquis,James F. Smothers,Axel Hoos,John Bertin +43 more
TL;DR: A linking strategy to synergize the effect of two symmetry-related amidobenzimidazole-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function is developed, representing a milestone in the rapidly growing field of immune-modifying cancer therapies.
Journal ArticleDOI
Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Connie L. Erickson-Miller,Evelyne Delorme,Shin-Shay Tian,Christopher B. Hopson,Amy J. Landis,Elizabeth I. Valoret,Teresa S. Sellers,Jon Rosen,Stephen G. Miller,Juan I. Luengo,Kevin J. Duffy,Julian Jenkins +11 more
TL;DR: In conclusion, eltrombopag interacts selectively with the TpoR without competing with Tpo, leading to the increased proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes and increased platelet production.
Journal ArticleDOI
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Harriet S. Walter,Simon Rule,Martin J. S. Dyer,Lionel Karlin,Ceri Jones,Bruno Cazin,Philippe Quittet,Nimish Shah,Claire V. Hutchinson,Hideyuki Honda,Kevin J. Duffy,Joseph Birkett,Virginia Jamieson,Nigel Courtenay-Luck,Toshio Yoshizawa,John Sharpe,Tomoya Ohno,Shin-ichiro Abe,Akihisa Nishimura,Guillaume Cartron,Franck Morschhauser,Christopher Fegan,Gilles Salles +22 more
TL;DR: ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity and should confer advantages in combination therapies.
Journal ArticleDOI
Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase *
Dashyant Dhanak,Kevin J. Duffy,Victor K. Johnston,Juili Lin-Goerke,Michael G. Darcy,Antony N. Shaw,Baohua Gu,Carol Silverman,Adam T. Gates,Michael R. Nonnemacher,David L. Earnshaw,David J. Casper,Arun C. Kaura,Audrey Baker,Cathy Greenwood,Lester L. Gutshall,Derrick Maley,Alfred DelVecchio,Ricardo Macarron,Glenn A. Hofmann,Zaid Alnoah,Hung-Yuan Cheng,George M. Chan,Sanjay S. Khandekar,Richard M. Keenan,Robert T. Sarisky +25 more
TL;DR: A biochemical RNA synthesis assay was established to identify potential polymerase inhibitors from a high throughput screen of the GlaxoSmithKline proprietary compound collection, finding the benzo-1,2,4-thiadiazine compound 1 to be a potent, highly specific inhibitor of NS5B.